NORTHSTAR ASSET MANAGEMENT Co Sells 3,390 Shares of Danaher Corporation $DHR

NORTHSTAR ASSET MANAGEMENT Co lowered its stake in Danaher Corporation (NYSE:DHR) by 10.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 28,995 shares of the conglomerate’s stock after selling 3,390 shares during the period. Danaher comprises 1.2% of NORTHSTAR ASSET MANAGEMENT Co’s holdings, making the stock its 17th largest position. NORTHSTAR ASSET MANAGEMENT Co’s holdings in Danaher were worth $5,749,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in DHR. Mccarter Private Wealth Services LLC boosted its stake in shares of Danaher by 27.2% in the 3rd quarter. Mccarter Private Wealth Services LLC now owns 2,795 shares of the conglomerate’s stock worth $554,000 after buying an additional 598 shares during the last quarter. Kathmere Capital Management LLC lifted its holdings in Danaher by 23.7% in the third quarter. Kathmere Capital Management LLC now owns 1,573 shares of the conglomerate’s stock valued at $312,000 after acquiring an additional 301 shares during the period. Gladstone Institutional Advisory LLC boosted its position in Danaher by 6.9% in the third quarter. Gladstone Institutional Advisory LLC now owns 7,451 shares of the conglomerate’s stock worth $1,477,000 after purchasing an additional 483 shares during the last quarter. Gries Financial LLC grew its stake in shares of Danaher by 20.0% during the 3rd quarter. Gries Financial LLC now owns 1,694 shares of the conglomerate’s stock valued at $336,000 after purchasing an additional 282 shares during the period. Finally, Autumn Glory Partners LLC increased its position in shares of Danaher by 28.2% during the 3rd quarter. Autumn Glory Partners LLC now owns 1,365 shares of the conglomerate’s stock valued at $271,000 after purchasing an additional 300 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 30,248 shares of company stock worth $6,609,663 in the last three months. 11.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on DHR shares. KeyCorp reissued an “overweight” rating on shares of Danaher in a report on Thursday, December 18th. HSBC lifted their price target on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Bank of America reduced their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. Redburn Partners set a $220.00 target price on Danaher in a report on Wednesday, October 8th. Finally, Morgan Stanley began coverage on Danaher in a report on Monday, December 1st. They set an “overweight” rating and a $270.00 price target for the company. Twenty-one investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $249.50.

Danaher Stock Up 0.5%

DHR opened at $236.60 on Wednesday. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a market cap of $167.12 billion, a price-to-earnings ratio of 48.78, a price-to-earnings-growth ratio of 4.19 and a beta of 0.89. The firm’s fifty day moving average is $224.48 and its 200 day moving average is $209.87.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period last year, the firm earned $1.71 earnings per share. The business’s quarterly revenue was up 4.4% on a year-over-year basis. On average, sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.5%. Danaher’s payout ratio is currently 26.39%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.